Comprehensive Variant Screening of the UGT Gene Family

키워드

참고문헌 (43)

1. King CD, "UDP-glucuronosyltransferases", Curr Drug Metab, 1, pp.143~161 (2000)
2. Liston HL, "Drug glucuronidation in clinical psychopharmacology", J Clin Psychopharmacol, 21, pp.500~515 (2001)
3. Baranano DE, "Biliverdin reductase: a major physiologic cytoprotectant", Proc Natl Acad Sci U S A, 99, pp.16093~16098 (2002)
4. Lacko M, "Combined effect of genetic polymorphisms in phase I and II biotransformation enzymes on head and neck cancer risk", Head Neck, 35, pp.858~867 (2013)
5. Bajro MH, "Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer", Cancer Genet, 205, pp.163~167 (2012)
6. Gil J, "Gilbert syndrome: the UGT1A1*28 promoter polymorphism as a biomarker of multifactorial diseases and drug metabolism", Biomark Med, 6, pp.223~230 (2012)
7. Lin R, "Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population", Pharmacogenet Genomics, 19, pp.310~318 (2009)
8. Mackenzie P, "Glucosidation of hyodeoxycholic acid by UDP-glucuronosyltransferase 2B7", Biochem Pharmacol, 65, pp.417~421 (2003)
9. Barre L, "Substrate specificity of the human UDP-glucuronosyltransferase UGT2B4 and UGT2B7. Identification of a critical aromatic amino acid residue at position 33", FEBS J, 274, pp.1256~1264 (2007)
10. Lin GF, "An association of UDP-glucuronosyltransferase 2B7 C802T (His268Tyr) polymorphism with bladder cancer in benzidine-exposed workers in China", Toxicol Sci, 85, pp.502~506 (2005)
11. van der Logt EM, "Genetic polymorphism in UDP-glucuronosyltransferase 2B7 and colorectal cancer risk", Oncol Res, 17, pp.323~329 (2009)
12. Parmar S, "Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer", Breast Cancer Res, 13, pp.R57~ (2011)
13. Green MD, "Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates", Drug Metab Disp, 22, pp.799~805 (1994)
14. Chung JY, "Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers", CLINICAL PHARMACOLOGY THERAPEUTICS, 77(6), pp.486~494 (2005), MOSBY
15. Court MH, "UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver", J Pharmacol Exp Ther, 310, pp.656~665 (2004)
16. Rozen S, "Primer3 on the WWW for general users and for biologist programmers", Methods Mol Biol, 132, pp.365~386 (2000)
17. Devlin B, "A comparison of linkage disequilibrium measures for fine-scale mapping", Genomics, 29, pp.311~322 (1995)
18. Barrett JC, "Haploview: analysis and visualization of LD and haplotype maps", Bioinformatics, 21, pp.263~265 (2005)
19. Yuan HY, "FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization", Nucleic Acids Res, 34, pp.W635~W641 (2006)
20. Sugatani J, "Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia", Biochem Biophys Res Commun, 292, pp.492~497 (2002)
21. Gagné JF, "Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)", Mol Pharmacol, 62, pp.608~617 (2002)
22. Jinno H, "Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D", Drug Metab Dispos, 31, pp.108~113 (2003)
23. Ando Y, "Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis", Cancer Res, 60, pp.6921~6926 (2000)
24. Miners JO, "Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug", Cancer Res, 57, pp.284~289 (1997)
25. Zhou S, "Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid", Biochem Pharmacol, 65, pp.1853~1865 (2003)
26. Zhang JY, "Involvement of human UGT2B7 and 2B15 in rofecoxib metabolism", Drug Metab Dispos, 31, pp.652~658 (2003)
27. Court MH, "Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9", Drug Metab Dispos, 30, pp.1257~1265 (2002)
28. Thiagalingam A, "RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas", Mol Cell Biol, 16, pp.5335~5345 (1996)
29. Yuan P, "Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer", Cancer, 110, pp.2682~2690 (2007)
30. Kim K, "Induction of the transcriptional repressor ZBTB4 in prostate cancer cells by drug-induced targeting of microRNA-17-92", 106b-25clusters, 2012, pp.11, 1852~1862
31. Chen H, "Up-regulation of UDP-glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy", Drug Metab Dispos, 37, pp.1841~1847 (2009)
32. Gregory PA, "Regulation of UDP glucuronosyltransferases in the gastrointestinal tract", Toxicol Appl Pharmacol, 199, pp.354~363 (2004)
33. Takahashi N, "Amino acid substitutions in genetic variants of human serum albumin and in sequences inferred from molecular cloning", Proc Natl Acad Sci U S A, 84, pp.4413~4417 (1987)
34. Hishinuma A, "Missense mutation (C1263R) in the thyroglobulin gene causes congenital goiter with mild hypothyroidism by impaired intracellular transport", Endocr J, 45, pp.315~327 (1998)
35. Mendel D, "Probing protein stability with unnatural amino acids", Science, 256, pp.1798~1802 (1992)
36. Bosma PJ, "The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome", N Engl J Med, 333, pp.1171~1175 (1995)
37. Swen JJ, "Pharmacogenetics: from bench to byte--an update of guidelines", Clin Pharmacol Ther, 89, pp.662~673 (2011)
38. Chen G, "UGT1A1 is a major locus influencing bilirubin levels in African Americans", Eur J Hum Genet, 20, pp.463~468 (2012)
39. Aono S, "Identification of defect in the genes for bilirubin UDP-glucuronosyl-transferase in a patient with Crigler-Najjar syndrome type II", Biochem Biophys Res Commun, 197, pp.1239~1244 (1993)
40. Aono S, "Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert’s syndrome", Lancet, 345, pp.958~959 (1995)
41. Saeki M, "Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population", Drug Metab Dispos, 32, pp.1048~1054 (2004)
42. Duguay Y, "A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity", Clin Pharmacol Ther, 75, pp.223~233 (2004)
43. Lévesque E, "Isolation and characterization of UGT2B15(Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene", Pharmacogenetics, 7, pp.317~325 (1997)

관련 논문AI추천